



Infectious Diseases Working Party

Chair: Dina Averbuch (IL) **Secretary:** Jan Styczynski (PL)

Study Coordinator Lead: Nina Knelange (NL) **Statisticians:** Gloria Tridello (IT)

Study Coordinators: Inge Verheggen (NL) **Nurse:** Juana Schwartz Mota (ES)

Lotus Wendel (NL)



Major Achievements

IDWP in 2025

During 2025, seven European Conference on Infections in Leukemia (ECIL) guidelines were published providing recommendations on the management of Viral hepatitis (Mikulska), CMV (Ljungman), post-pandemic management of COVID (Cesaro), *Clostridioides difficile* (Mikulska), Empirical and targeted therapy of febrile neutropenia (Averbuch), Community-acquired respiratory viruses (von Lilienfeld-Toal), and Antifungal prophylaxis (Pagano). Published in top-ranked medical journals, including *The Lancet group*, *Leukemia*, and the *Journal of Infection*

Overall, in 2025, the IDWP had 18 **publications**, with an IF of >200, and 7 oral and 4 poster **presentations at international conferences**.



Dan Engelhard, is awarded **EBMT Honorary Member**

Dan Engelhard

The IDWP has successfully performed the EBMT pilot study on HIV in **StudyManager**; the new tool for electronic data collection, former MED-C, within the Registry. (~170 cases)

At the **51st EBMT Annual Meeting** in Florence, Italy, the educational session on viral infections was ranked among the top 10 most attended in-person sessions and infectious complications ranked first among the top ten categories of submitted abstracts.

In November 2025, we welcomed the IDWP community in Würzburg, Germany, for the **28th IDWP-EBMT Educational Course**, with 129 attendees from 29 different countries all over the world, organized by Daniel Teschner. Twelve young physicians presented challenging cases, and four educational grants were awarded by EBMT



Young Investigators are actively involved in IDWP studies with the supervision of a senior investigator (some of our excellent 2025 YIs: Annalisa Paviglianiti, Fabio Andreozzi, Giulia Ferrando, Jop Jans, Silvia Simo, Yuri Vanbiervliet)

In 2025, the infection topics on the **data collection forms** (Registry) underwent a major revision to accommodate data reporters and to enable usable exports for future studies.

The 'IDWP team' as mentioned at the top of this poster cannot function without close collaboration with our **IDWP Board**, made up of leading **infection experts** in the field. They have helped setting up studies, guided younger investigators, and helped revising the infection-related data collection forms. We want to thank: Catherine, Dionysios, Jose Luis, Lidia, Malgorzata, Per, Rafael and Simone for their effortless help.

Key publications in the past year

- Tuberculosis after HCT: a retrospective study. J. Drozd-Sokolowska et al. BMT
- Clinical characteristic and outcome of HHV-6 encephalitis after allo-HCT. K. Perruccio et al. BMT
- Progressive Multifocal Leukoencephalopathy (PML) after HCT. J. Dybko et al. BMT
- A survey on hemorrhagic cystitis in patients after alloHSCT. S. Cesaro et al. BMT
- Prevention and management of CMV infections in pediatric HSCT J. Styczynski et al. BMT.
- Neglected Tropical Diseases (NTDs) and related infections in HCT in adults and children survey. J. Snowden et al. BMT
- Harmonized definitions of pneumonia in allo-HCT. D. Neofytos et al. CurrResTranslMed
- Bloodstream and CVC-related infections. D. Averbuch et al. CMI

Currently ongoing studies

- HIV-positive patients undergoing HCT (A. Paviglianiti)
- Bacterial and fungal infections in CAR-T – GoCART part II (C. Oltolini, M. Mikulska, D. Averbuch)
- CMV and NRM in CART (R. de la Camara, P. Ljungman, D. Averbuch; in collaboration with LWP, CTIWP)

Join the IDWP

We invite everyone interested to join the **IDWP LinkedIn Group**. Get updated on the latest publications, ECIL-guidelines, hot topics, upcoming events, launched IDWP studies, and other infection related information. Moreover, expand your network with professionals who share your interests and goals. Great things happen when passionate people come together (<https://www.linkedin.com/groups/16179130/>)

28th IDWP Educational course



IDWP plans for 2026

Studies to be started soon

- Carbapenem-resistant bacteremia in colonised/previously infected patients (M. Mikulska)
- *Scedosporium* and *Lomentospora* infections after HCT (S. Cesaro, M.P. Esposto)
- Incidence and outcome of fungemia due to rare yeasts and cryptococcosis in HCT recipients (M. Mikulska, C. Bartalucci)
- Invasive *Mucormycetes* infection in HCT recipients (A. Xhaard, S. Corcione)

Publications in 2026 until February 2026

- Real-world utilization pattern and outcomes of letermovir in adult cytomegalovirus-seropositive allogeneic HCT recipients. J. Styczynski et al. TID
- Central Nervous System disorders following HSCT: prospective observational trial. M. Schmidt-Hieber et al. eClinMed
- Post-transplant haemorrhagic cystitis in patients who undergo allogeneic HSCT, part 2. s. Cesaro et al. BMT
- Length of SARS-CoV-2 shedding in HCT recipients. M. Mikulska et al. BMT

Educational activities in 2026

- Webinar on RSV Vaccines – March 10, 17:00 – 18:00
- The 29th IDWP-EBMT Educational Course, 19 – 21 November 2026, Madrid, Spain
Local organizer: Rafael de la Camara – Joint course with TCWP

52nd Annual Meeting of EBMT (22 March – 25 March, Madrid, Spain)

IDWP-organised sessions

IDWP Business Meeting

Mon, March 23, 7.00-8.45h

IDWP Working Party Session

Mon, March 23, 14.30-15.45h

Chairs: Dina Averbuch and Jan Styczynski

P. Ljungman – Refractory/resistant HSV and CMV – an underestimated problem?

M. Rovira – Specifics of infections management in patients following post-transplant cyclophosphamide

D. Neofytos – Antifungal/antiviral/antibacterial prophylaxis update

M. Mikulska – Top 10 papers 2025-2026 on new antibiotics and other infectious topics

Other Infection-related sessions

- **NG04. Nurses: advances in not so rare complications** Sun, March 22, 14.30-16.00h

Advances in diagnosis and care of hemorrhagic cystitis / advances in case or severe skin toxicity and skin GvHD / advances in prevention detection and treatment of graft failure / Advances in prevention, detection and treatment of viral complications

- **MTE-1. Meet-the-Expert** Mon, March 23, 7.45-08.45h

Infection prevention and management in HCT and Cell Therapy (O. Cornely & P. Munoz)

- **E01. Educational – Infections after HCT/CT** Mon, March 23, 9.00-10.30h

When fever isn't an infection, rethinking diagnostic assumptions / When fever signals infection, how to select empirical antibiotic therapy / New antifungals in the horizon, expanding the armamentarium / New antivirals and unmet challenges

- **Pharm1. – Pharmacists Day 1 Clinical update** Mon, March 23, 9.00-10.30h

Pharm1-4. Beyond CMV – management of viral infections in the transplant setting

- **MTE-6. Meet-the-Expert** Tue, March 24, 7.45-08.45h

CMV: evolving strategies for diagnosis and management (P.Ljungman & D. Navarro)

- **W06. Workshop – Infections after CAR-T therapy** Tue, March 24, 11.00-12.30h

Shall we treat febrile patients following CAR-T infusion with antibiotics / Shall we worry about fungal infections in CAR-T patients / Shall we monitor viral infections in CAR-T recipients and which ones / Shall we vaccinate after CAR-T to prevent delayed infections

- **E10. Educational – Beware of unusual infections** Tue, March 24, 16.30-18.00h

MDR bacterial infections / Rare fungal infections / Mycobacterial infection / Rare viral infections

- **E11. Educational – Neurologic complications** Tue, March 24, 16.30-18.00h

Neurologic complications of allo-HCT / Neurologic complications of CAR-T therapy / Neurologic complications of bispecific antibodies and other immunotherapies / Neurologic (CNS) infections

- **SS06. Global Committee Scientific Session** Tue, March 24, 16.30-18.00h

SS6-1 EBMT IDWP project on neglected tropical diseases (NTD) and related diseases

- **E14. Educational – Fungal infections after HCT** Wed, March 25, 8.30-10.00h

Growing global concern over the spread of Aspergillus resistance / What a HCT physician needs to know about fungal diagnosis / Antifungal therapy in practice: when is it time to change / Fungal infections after HCT: what's new

- **NG24. Nurses - Infections** Wed, March 25, 8.30-10.00h

Curing the incurable stem cell transplantation for HIV / How to prevent and manage antibiotic resistance in cellular therapy / How donor registries can prepare for an endemic or pandemic virus / Challenges and treat of fungal infection in LMIC

IDWP-affiliated oral presentations

- **OS09. Infections - Viral** Tue, March 24, 09.00-10.15h

OS09-03 - A. Paviglianiti – Outcome of adult patients with HIV undergoing autologous or allogeneic HCT: a retrospective multicentre study

OS09-06 - R. de la Cámara – Impact of CMV infection in patients with lymphoma after CAR-T therapy

OS09-08 - A. Paviglianiti – Maribavir for clinically significant cytomegalovirus infection in allogeneic HCT: a retrospective international real-world study

- **OS19. Infections - Bacterial, fungal and vaccines** Wo, March 25, 12.30-13.45h

OS19-01 - F. Andreozzi – Toxoplasmosis screening, prophylaxis and treatment practices across EBMT centers

OS19-04 - A. Piekarska – Vaccination strategy in patients undergoing CAR-T therapy

OS19-08 - J. Jans – Pre-transplant aspergillosis is associated with reduces post-transplant survival of children with leukemia – subgroup analyses

IDWP-affiliated poster presentations

B082 - A. Piekarska – Bronchoalveolar lavage practices in allo-hct recipients with lower respiratory tract infections

B092 - M. Stamouli – Survey on the use of recombinant herpes zoster vaccine after autologous and allogeneic HSCT

Contact: idwp@ebmt.org

www.ebmt.org